A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries. On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq). On March 12, 2017, ChromaDex Corporation acquired Healthspan Research LLC, a consumer product company offering Tru Niagen® branded products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 129M | 129M | 100M | 84M | 72M | 67M |
| Net Income | 17M | 17M | 8.6M | -4.9M | -17M | -27M |
| EPS | $0.20 | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 |
| Free Cash Flow | 14M | 14M | 12M | 7.1M | -15M | -24M |
| ROIC | 132.4% | 132.4% | 511.7% | -17.3% | -57.6% | -85.5% |
| Gross Margin | 64.3% | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | 16M | 16M | 7.7M | -5.6M | -19M | -27M |
| Operating Margin | 12.6% | 12.6% | 7.8% | -6.7% | -25.9% | -40.1% |
| ROE | 22.7% | 28.3% | 18.5% | -17.4% | -57.7% | -85.5% |
| Shares Outstanding | 87M | 87M | 78M | 71M | 69M | 68M |
Niagen Bioscience, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Niagen Bioscience, Inc. trades at 42.6x trailing earnings, compared to its 15-year median P/E of 50.2x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 30.1x vs a median of 25.1x. The company's 5-year average gross margin is 61.6%. At current prices, the estimated annualized return to fair value is +38.2%.
Niagen Bioscience, Inc. (NAGE) has a current P/E ratio of 42.6, compared to its historical median P/E of 50.2. The stock is currently considered Cheap based on its historical valuation range.
Niagen Bioscience, Inc. (NAGE) has a 5-year average return on invested capital (ROIC) of -7.0%. This is below average and may indicate limited pricing power.
Niagen Bioscience, Inc. (NAGE) has a market capitalization of $408M. It is classified as a small-cap stock.
Niagen Bioscience, Inc. (NAGE) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.06%.
Based on historical P/E analysis, Niagen Bioscience, Inc. (NAGE) appears cheap. The current P/E of 42.6 is 15% below its historical median of 50.2. The estimated fair value CAGR (P/E method) is 84.5%.
Niagen Bioscience, Inc. (NAGE) operates in the Medicinal Chemicals & Botanical Products industry, within the Healthcare sector.
Niagen Bioscience, Inc. (NAGE) reported annual revenue of $129 million in its most recent fiscal year, based on SEC EDGAR filings.
Niagen Bioscience, Inc. (NAGE) has a net profit margin of 13.4%. This is a healthy margin.
Niagen Bioscience, Inc. (NAGE) generated $14 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Niagen Bioscience, Inc. (NAGE) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Niagen Bioscience, Inc. (NAGE) reported earnings per share (EPS) of $0.20 in its most recent fiscal year.
Niagen Bioscience, Inc. (NAGE) has a return on equity (ROE) of 28.3%. This indicates the company generates strong returns for shareholders.
Niagen Bioscience, Inc. (NAGE) has a 5-year average gross margin of 61.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for Niagen Bioscience, Inc. (NAGE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Niagen Bioscience, Inc. (NAGE) has a book value per share of $0.88, based on its most recent annual SEC filing.